Objective To assess the effectiveness and safety of antiplatelet drugs for prevention of pre-eclampsia and its consequences. Design Systematic review. Data sources Register of trials maintained by Cochrane Pregnancy and Childbirth Group, Cochrane Controlled Trials Register, and Embase. Included studies Randomised trials involving women at risk of pre-eclampsia, and its complications, allocated to antiplatelet drug(s) versus placebo or no antiplatelet drug. Main outcomes measures Pre-eclampsia, preterm birth, fetal or neonatal death, and small for gestational age baby. Studies were assessed for quality of concealment of allocation and losses to follow up. Results 39 trials (30 563 women) were included, and 45 trials ( > 3000 women) excluded. Use of antiplatelet drugs was associated with a 15% reduction in the risk of pre-eclampsia (32 trials, 29 331 women; relative risk 0.85, 95% confidence interval 0.78 to 0.92; number needed to treat 100, 59 to 167). There was also an 8% reduction in the risk of preterm birth (23 trials, 28 268 women; 0.92, 0.88 to 0.97; 72, 44 to 200), and a 14% reduction in the risk of fetal or neonatal death (30 trials, 30 093 women; 0.86, 0.75 to 0.98; 250, 125 to > 10 000) for women allocated antiplatelet drugs. Small for gestational age babies were reported in 25 trials (20 349 women), with no overall difference between the groups (relative risk 0.92, 0.84 to 1.01). There were no significant differences in other measures of outcome. Conclusions Antiplatelet drugs, largely low dose aspirin, have small to moderate benefits when used for prevention of pre-eclampsia.
Introduction
Pre-eclampsia, defined as hypertension associated with proteinuria, 1 complicates 2-8% of pregnancies. 2 Although the outcome for most women is good, severe pre-eclampsia and eclampsia (the rare occurrence of seizures superimposed on pre-eclampsia) are important causes of maternal mortality, being associated with 10-15% of maternal deaths. 3 4 Perinatal mortality is also increased. 5 There is little good quality information about maternal and perinatal morbidity, but it also is probably high. For the one in ten women who develop pregnancy induced hypertension (raised blood pressure without proteinuria), the outcome is similar to that for women with normal blood pressure. 6 The cause of pre-eclampsia remains unknown, but the condition is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a platelet derived vasoconstrictor and stimulant of platelet aggregation. 7 These observations led to the hypothesis that antiplatelet drugs might prevent or delay the development of pre-eclampsia. This hypothesis has been widely tested in randomised trials. Exciting results from early small trials led on to several large studies of low dose aspirin. However, the collaborative low dose aspirin study in pregnancy, the largest trial to date, failed to confirm any worthwhile benefit. w11 Previous systematic reviews, all now out of date, concluded that although low dose aspirin seems safe, it is not effective for most women. [8] [9] [10] [11] [12] [13] Issues such as whether there is greater benefit for high risk women, what dose to use, and when to start treatment remain controversial, and publication bias has been suggested as a possible explanation of the discrepancy between the results of early metaanalyses and later large trials. 14 This systematic review is published in full in the Cochrane Library. 15 The aim was to assess the effects of antiplatelet drugs for the prevention of pre-eclampsia and its complications. We also explored the extent to which publication bias may have influenced speed and accessibility of the results of these trials.
Methods

Search strategy
The full search strategy is described elsewhere. 15 The search included the Cochrane Pregnancy and Childbirth Group register of trials, the Cochrane Controlled Trials Register, 16 Embase (1994-9), and hand searching of conference abstracts. We included randomised trials comparing antiplatelet agent(s) with placebo or no antiplatelet agent for women at risk of developing preeclampsia. Quasi random designs were excluded. Main outcomes were pre-eclampsia, preterm delivery, stillbirth or neonatal death, and a small for gestational age baby.
Assessment of validity
The studies were assessed independently by two reviewers. There was no blinding of authors or results. The four of us worked in pairs, one based in the United Kingdom and the other in Australia. Differences were resolved by discussion between the pair. If differences could not be resolved, the other pair was consulted.
We assessed the validity of each included trial according to the criteria outlined in the Cochrane handbook, 17 giving each trial a grade for concealment of allocation: a (adequate), b (unclear), or c (clearly inadequate). If the method of concealment was unclear, we tried to contact authors for further details. Losses to follow up were documented, and we excluded studies or outcomes for which over 20% of participants were not reported.
Abstraction and synthesis of data
We all independently extracted data from the papers, working in pairs. Discrepancies were resolved by discussion. If we could not agree, the data were excluded until further clarification was available from A Prespecified outcomes for the women were pre-eclampsia, caesarean section, antepartum haemorrhage, serious maternal morbidity, and rare adverse events. For the babies, outcomes were death (stillbirth, neonatal, or infant), preterm birth ( < 37 completed weeks), small for gestational age, bleeding episodes, and measures of infant and child development. Assessment of the use of health service resources included antenatal hospital admission, and admission to a special care baby unit.
We analysed the results with Cochrane Collaboration RevMan software (Metaview 3.1) using a fixed effects model. Results are presented as summary relative risk, risk difference, and number needed to treat, which is calculated as 1/risk difference. Graphs were sorted by effect size to assess potential asymmetry in their distribution.
Women were classified into prespecified subgroups based on whether they were at high or moderate risk of developing pre-eclampsia at trial entry, were before or after 20 weeks gestation at trial entry, the dose of aspirin was <75mg or > 75mg, and the study used a placebo for the control group. High risk of preeclampsia was defined as one or more of previous severe pre-eclampsia, diabetes, chronic hypertension, renal disease, or autoimmune disease. Moderate risk was defined as any other risk factors. When risk was unclear or unspecified, women were classified as moderate risk.
Studies were divided by whether they were published before or after the end of 1994, when the collaborative low dose aspirin study in pregnancy w11 was published, and classified according to where the main report was published and number of citations. Date recruitment stopped was compared with date and place of publication.
Results
The search strategy yielded 310 citations. Of these, 153 were excluded; 44 were duplicate citations and 109 did not meet the eligibility criteria. Of the remaining 157, 99 referred to a total of 39 included trials and 58 referred to 45 excluded studies (fig 1) .
The 39 included trials recruited 30 563 women. Thirteen trials included fewer than 50 women, five included 50-99 women, 13 included 100-999 women, and eight included 1000 or more women. There was a wide range in risk status between women in the different studies and, often, between women in the same trial. One study did not report outcomes separately for treatment and prevention and so we included all women. 18 Details of the methods, participants, interventions, and outcomes of the included studies are available on the BMJ 's website. Most studies compared aspirin alone with placebo (28 802 women). Four studies used a combination of aspirin and dipyridamole compared with control, one used heparin with dipyridamole compared with control, and another compared ozagrel hydrochloride with placebo. Thirteen small trials used > 75 mg aspirin (1264 women). Eight trials did not use a placebo. Details of the 45 excluded studies have been published. 15 Figure 1 gives the reasons for exclusion.
Quantitative data synthesis
There was good agreement between reviewers for selection and assessment of validity, and discrepancies were quickly resolved. Concealment of allocation was graded a for 14 trials, b for 24, and c for one study. Data for all outcomes and subgroups are available. 15 
Maternal outcomes
There was no overall difference in the risk of pregnancy induced hypertension in the 27 trials (18 147 women) reporting this outcome (relative risk 0.97, 95% confidence interval 0.89 to 1.05). The 15% reduction in risk of pre-eclampsia associated with antiplatelet drugs (32 trials, 29 331 women; relative risk 0.85 95% confidence interval 0.78 to 0.92; risk difference − 0.01, 95% confidence interval − 0.017 to − 0.006; number needed to treat 100, 95% confidence interval 59 to 167) was consistent regardless of risk status (fig 2) , dose of aspirin, gestation at trial entry, or use of a placebo. It was greater for women allocated > 75 mg aspirin (relative risk 0.35, 0.24 to 0.52), but the numbers in this subgroup are small (13 trials, 1264 women).
There were no significant differences between treatment and control groups in the risk of eclampsia (nine trials, 14 623 women), maternal death (two trials, 9438 women), caesarean section (17 trials, 25 827 women), induction of labour (three trials, 15 935 women), antenatal admission (one trial, 6049 women), or placental abruption (12 trials, 22 309 women).
Outcomes for babies
In 23 trials (28 268 women) that reported preterm birth there was a small (8%) reduction in the risk of being born too early (relative risk 0.92, 0.88 to 0.97; risk difference − 0.014, − 0.023 to − 0.005; number needed to treat 72, 44 to 200; fig 3) . The size of this reduction was consistent across all subgroups, except those receiving > 75 mg aspirin (557 women; relative risk 0.58, 0.38 to 0.88).
Thirty trials (30 093 women) reported fetal, neonatal, or infant deaths. Overall there was a 14% reduction in deaths in the antiplatelet group compared with the control group (relative risk 0.86, 0.75 to 0.98; risk difference -0.004,-0.008 to 0.000; number needed to treat 250, 125 to > 10 000; fig 4) .
In 25 trials (20 349 women) there was no clear difference in the risk of small for gestational age births (relative risk 0.92, 0.84 to 1.01; fig 5) . In two subgroups the difference was significant: women randomised before 20 weeks (8401 women, 0.82, 0.71 to 0.96) and those given > 75 mg aspirin (934 women, 0.68, 0.52 to 0.88).
There were no significant differences between treatment and control groups in the risk of birth weight < 2500 g (4 trials, 7391 women), admission to special care baby unit (12 trials, 25 641 women), intraventricular haemorrhage (eight trials, 22 793 women), or other neonatal bleeding (six trials, 23 591 women). One large trial assessed child health and development at 12-18 months, no difference was apparent between treatment and control groups.
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Potential publication bias Twenty three included studies were published before the end of 1994 and 16 after the start of 1995 (table) . The early trials were more likely to be published in a high profile general journal (11/23 v 1/16) and to be available only as an abstract (6/23 v 1/16). In comparison, 36 excluded studies were published before the end of 1994 and nine after the start of 1995. Early excluded studies were more likely to be published as an abstract only (12/36 v 0/9) and to be known about only through prospective registration (6/36 v 0/9). started and stopped, and so assessment of potential bias in the speed with which results were published is not possible.
Discussion
Our review of data from over 30 000 women suggests that antiplatelets drugs are associated with a moderate (15%) reduction in the risk of pre-eclampsia, a 14% reduction in the risk of a stillbirth or neonatal death, and an 8% reduction in the risk of preterm birth. There was some evidence that there may be greater benefits for women given > 75 mg aspirin, although the numbers of women in the subgroup were small and so there is potential for random error. Also, the risks of this dose may be increased as current data on safety applies largely to 60 mg aspirin.
The relatively large number of subgroups, although pre-specified, means that some of the significant results may reflect the play of chance. In addition, there is potential for misleading bias in analyses for which only a proportion of eligible trials reported the outcome and large numbers of women were missing.
For aspirin to prevent pre-eclampsia it may need to be started well before trophoblast invasion is complete. We presented data before and after 20 weeks, as this is how they are reported in the trials, but there is little evidence of clinically worthwhile differences. The crucial time for starting treatment may be before 16 or even 12 weeks. This review includes women with a wide range of clinical risk. Although this enhances the generalisability of the results, it is not possible to disentangle the effects for women with specific conditions or risk factors. Such an analysis requires data from individual women and is now being planned.
The discrepancy between the results of early metaanalyses of antiplatelet drugs and later large trials has been quoted as an example of a misleading meta-analysis. 20 One plausible explanation for this discrepancy is publication bias. For example, only four of the 32 included trials that reported pre-eclampsia have a point estimate favouring the control group. Publication bias may be the reason for this lack of negative trials. Eighteen excluded studies are available only through abstracts or prospective registration. These may be missing negative results. An alternative explanation for the discrepancy is a different case mix in small and large trials. 21 The small trials included only high risk women who really benefited from antiplatelet drugs, whereas in the later large trials these effects were diluted by moderate risk women with little potential for benefit.
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Implications
As most of the evidence relates to aspirin ( < 75 mg), this is the antiplatelet drug of choice. Data from this review should be made available to pregnant women as well as clinicians and policy makers. As the reductions in risk are moderate, relatively large numbers of women will need to be treated to prevent a single adverse outcome. For example, the point estimate is that 250 women need to be treated to prevent the death of one baby, but the true number could be anywhere between 125 and 10 000 women. From a public health perspective, however, even these moderate benefits may be worth while. Starting 
What is already known on this topic
Early systematic reviews of antiplatelet drugs, largely low dose aspirin, included only small trials and reported promising reductions in the risk of developing pre-eclampsia and its complications Subsequent large trials have failed to confirm a large reduction in the risk of pre-eclampsia Successive meta-analyses have concluded that aspirin is not effective
What this study adds
Data from over 30 000 women show that antiplatelet drugs are associated with a 15% decrease in the risk of pre-eclampsia These drugs also have a small effect on the risk of stillbirth, neonatal death, and prematurity Data from individual women need to be reviewed to identify which women are most likely to benefit, when treatment should be started, and at what dose treatment before 12 weeks and using higher doses cannot be recommended until more information is available about safety.
Remaining questions are whether small subgroups of high risk women might have greater benefit and whether earlier treatment or a higher dose would have additional benefits without an increase in adverse effects. These unresolved questions would be most efficiently answered by a review pooling data from individual women in the trials presented here rather than undertaking further trials.
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Endpiece
A local celebrity
It was an element in Doctor Sloper's reputation that his learning and his skill were very evenly balanced; he was what you might call a scholarly doctor, and yet there was nothing abstract in his remedies-he always ordered you to take something. Though he was felt to be extremely thorough, he was not uncomfortably theoretic; and if he sometimes explained matters rather more minutely than might seem of use to the patient, he never went so far (like some practitioners one had heard of) as to trust to the explanation alone, but always left behind him an inscrutable prescription. There were some doctors that left the prescription without offering any explanation at all; and he did not belong to that class either, which was after all the most vulgar. It will be seen that I am describing a clever man: and this is really the reason why Doctor Sloper had become a local celebrity.
Henry James, Washington Square, 1880
Submitted by D R Laurence, emeritus professor of pharmacology and therapeutics, London
